Yufeng Ding

Yufeng Ding

Auto-generated profile, based on publicly available information

Yufeng Ding

Precise Genome Engineering Centre, School of Life Sciences, Guangzhou University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Nature Communications
Verified
Journal Article
Open access
MZMeixiao Zhan
Meixiao Zhan
YDYufeng Ding
Yufeng Ding
SHShanzhou Huang
Shanzhou Huang
YLYuhang Liu
Yuhang Liu
JXJing Xiao
Jing Xiao
XWXiongjun Wang
Xiongjun Wang
To overcome chemotherapy resistance, novel strategies sensitizing cancer cells to chemotherapy are required. Here, we screen the lysyl-oxidase (LOX) family to clarify its contribution to chemotherapy resistance in liver cancer. LOXL3 depletion significantly sensitizes liver cancer cells to Oxaliplatin by inducing ferroptosis. Chemotherapy-activated EGFR signaling drives LOXL3 to interact with TOM20, causing it to be hijacked into mitochondria, where LOXL3 lysyl-oxidase activity is reinforced by phosphorylation at S704. Metabolic adenylate kinase 2 (AK2) directly phosphorylates LOXL3-S704. Phosphorylated LOXL3-S704 targets dihydroorotate dehydrogenase (DHODH) and stabilizes it by preventing its ubiquitin-mediated proteasomal degradation. K344-deubiquitinated DHODH accumulates in mitochondria, in turn inhibiting chemotherapy-induced mitochondrial ferroptosis. CRISPR-Cas9-mediated site-mutation of mouse LOXL3-S704 to D704 causes a reduction in lipid peroxidation. Using an advanced liver cancer mouse model, we further reveal that low-dose Oxaliplatin in combination with the DHODH-inhibitor Leflunomide effectively inhibit liver cancer progression by inducing ferroptosis, with increased chemotherapy sensitivity and decreased chemotherapy toxicity.

7 June 2023 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
HYHua Yu
Hua Yu
TSTiezhu Shi
Tiezhu Shi
LYLinli Yao
Linli Yao
DXDongwei Xu
Dongwei Xu
YDYufeng Ding
Yufeng Ding
XWXiongjun Wang
Xiongjun Wang

24 April 2023 in The EMBO Journal
Verified
Journal Article
Closed access
KHKunhua Hu
Kunhua Hu
YDYufeng Ding
Yufeng Ding
HZHongwen Zhu
Hongwen Zhu
XJXiaoqian Jing
Xiaoqian Jing
WHWeiling He
Weiling He
XWXiongjun Wang
Xiongjun Wang